SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Array Biopharma, Inc -- Ignore unavailable to you. Want to Upgrade?

To: mcbio who wrote (203)11/9/2012 6:52:39 PM
From: tom pope  Read Replies (1) | Respond to of 321
 
As you suggested over on iHub, dilution is a fact of life in biotech investing. I wonder if anyone has ever tried to come up with a predictor from within what is known of a company's cash flow to forewarn of these unpleasant events.
This is my first one since DVAX, I think, so I've been lucky.



To: mcbio who wrote (203)11/9/2012 8:00:34 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 321
 
Thanks again!

True for all three pi3k-targeted Novartis molecules combo'd with 162, the bkm120 trial is already launched.....

clinicaltrials.gov


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News